Morphic Holding Inc (MORF)
33.46
+2.00
(+6.36%)
USD |
NASDAQ |
Jun 25, 16:00
33.46
0.00 (0.00%)
After-Hours: 20:00
Morphic Cash from Investing (Quarterly): 31.37M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 31.37M |
| December 31, 2023 | 12.88M |
| September 30, 2023 | -133.08M |
| June 30, 2023 | -133.22M |
| March 31, 2023 | -88.40M |
| December 31, 2022 | -1.146M |
| September 30, 2022 | -32.51M |
| June 30, 2022 | 3.278M |
| March 31, 2022 | -26.07M |
| December 31, 2021 | 5.186M |
| September 30, 2021 | -211.96M |
| June 30, 2021 | 19.85M |
| March 31, 2021 | 73.75M |
| Date | Value |
|---|---|
| December 31, 2020 | -11.30M |
| September 30, 2020 | -46.05M |
| June 30, 2020 | 41.91M |
| March 31, 2020 | 23.62M |
| December 31, 2019 | -44.20M |
| September 30, 2019 | 34.20M |
| June 30, 2019 | 17.68M |
| March 31, 2019 | -143.67M |
| December 31, 2018 | -0.164M |
| September 30, 2018 | -0.286M |
| June 30, 2018 | 0.025M |
| March 31, 2018 | -0.231M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-211.96M
Minimum
Sep 2021
73.75M
Maximum
Mar 2021
-23.21M
Average
1.066M
Median
Cash from Investing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | -67.62M |
| Cytokinetics Inc | 32.64M |
| Amicus Therapeutics Inc | 7.537M |
| Insmed Inc | 295.32M |
| Madrigal Pharmaceuticals Inc | 98.05M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -46.39M |
| Cash from Financing (Quarterly) | 0.911M |
| Free Cash Flow | -128.61M |
| Free Cash Flow Per Share (Quarterly) | -0.9411 |
| Free Cash Flow Yield | -8.27% |